Hepatic complications of antituberculosis therapy revisited.
Since 1973, when the incidence and pattern of adverse reactions to antituberculosis therapy were described by Rossouw and Saunders, para-amino-salicylic acid, the major cause of drug-induced hepatitis, has been withdrawn from the regimen used in Cape Town and replaced with pyrazinamide (PZA). Our study in the same hospital indicates that although the substitution has resulted in a significant reduction in the incidence of all side-effects (4,1% v. 9%; P less than 0,001), the incidence of hepatitis is unchanged (0,3%). PZA is currently the major cause of hepatitis associated with antituberculosis therapy.
D000293:Adolescent; D000328:Adult; D000368:Aged; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007223:Infant; D007538:Isoniazid / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011718:Pyrazinamide / Q000009:adverse effects*; D012293:Rifampin / Q000009:adverse effects*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D011718:Pyrazinamide; D007538:Isoniazid; D012293:Rifampin